Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 28Prostatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 10Sarcoma 9Lung Neoplasms 6Uterine Cervical Neoplasms 5Endometrial Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Pancreatic Neoplasms 3Neoplasms 3Liposarcoma, Myxoid 3Head and Neck Neoplasms 3Glioblastoma 3Carcinoma, Intraductal, Noninfiltrating 3Breast Carcinoma In Situ 3Urogenital Neoplasms 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Small Cell Lung Carcinoma 2Sarcoma, Synovial 2Radiation Injuries 2Neurofibrosarcoma 2Neoplasm Metastasis 2Melanoma 2Lymphatic Metastasis 2Liposarcoma 2Leiomyosarcoma 2Histiocytoma, Malignant Fibrous 2Fibrosarcoma 2Cholangiocarcinoma 2

Interventions

Gemcitabine 61Cisplatin 39Oxaliplatin 31Capecitabine 30Fluorouracil 22Leucovorin 20Irinotecan 12pembrolizumab 11130-nm albumin-bound paclitaxel 10durvalumab 9Erlotinib Hydrochloride 8Trastuzumab 7Bevacizumab 7Taxes 6Platinum 6Magnetic Resonance Spectroscopy 6Biopsy 6Albumin-Bound Paclitaxel 61,2-diaminocyclohexaneplatinum II citrate 6Specimen Handling 5Sorafenib 5Radiotherapy 5Docetaxel 5Carboplatin 5S 1 (combination) 4Immunohistochemistry 4Cyclophosphamide 4trifluridine tipiracil drug combination 3fludarabine 3dehydroftorafur 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Gallbladder Neoplasms × Radiation Dose Hypofractionation × Clear all
NCT04068194 2026-05-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

National Cancer Institute (NCI)

Phase 1/2 Active not recruiting
103 enrolled
Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡